Daniel Thomas

Research Interests

Cancer Biology and Clinical Oncology

Prof Daniel Thomas

Professor

School of Medicine

College of Health

With unique training experience at the Stanford University School of Medicine, Daniel Thomas is a clinical haematologist and cancer scientist whose goals are to develop new drugs and better outcomes for the treatment of rare and hard-to-treat cancers and lead a creative and innovative cancer research laboratory. The core values in Dan's lab are Creativity (not being afraid to try something new), Compassion (identifying with cancer patients and their carers to learn what really matters) and Generosity (sharing new technologies to other researchers to move the field forward).

Dan is currently Program Director for Blood Cancers at SAHMRI and leads the Myeloid Metabolism Lab located on Level 5 of the main SAHMRI building (Precision Medicine, Cancer Theme, adjacent to the Royal Adelaide Hospital and 10 minutes from Adelaide International Airport). The lab is focused on interplay between cancer, metabolism and epigenetics.  Dr Daniel Thomas is a clinical haematologist and pathologist whose goals in research are to develop new drugs for the treatment of cancer using expanded human myeloid progenitors, mass spectrometry and computational tools and has 6 filed patents for encompassing novel treatments for blood cancer. He has had post-doctoral training experience at the Stanford School of Medicine, Institute of Stem Cell & Regenerative Medicine, led by Irving Weissman and direct mentoring from Professor Ravindra Majeti (CD47 and pre-leukaemic stem cells). Key equipment accessible from Dan's laboratory including Seahorse Xfe96, Vistaflux software with Agilent 6546 Q-ToF metabolomics solution, BRAVO liquid handing robot, human metabolome shRNA bar-coded library, 10X single cell transcriptomics, ARIA FACS sorter & serial blood cancer patient samples.  If you are passionate about thinking outside the square to improve the treatment of cancer, please contact Dr Thomas about potential student internships.

The Thomas Lab has a strong track record in finding new druggable targets in cancer and predicting mutations that respond to specific targeted therapies as well as repurposing drugs for new uses in cancer. Some of the discoveries already in the clinic or are under clinical investigation, including a humanized monoclonal antibody for the treatment of myelofibrosis  (EMBO Reports, 2022), JAK2 mutations (Blood Cancer Discovery, 2023) and precision dietetics for IDH1 mutated cancers (Cancer Discovery, 2022) ( https://aacrjournals.org/bloodcancerdiscov/article-abstract/5/2/114/734869/IDH1-Mutant-Preleukemic-Hematopoietic-Stem-Cells?redirectedFrom=fulltext ) . Dan leads an international biannual conference, New Directions in Leukaemia Research (NDLR 2022 Brisbane, NDLR 2024 Adelaide and NDLR 2026 Adelaide) that brings scientists and doctors together to discover new treatments for blood cancers and leukaemia and the 5th National Cancer & Metabolism conference ( https://sahmri.org.au/australian-cancer-metabolism-meeting-2024).

Dan's lab is leading the first precision medicine trial nationwide for a rare and poor prognosis blood cancer called CMML (chronic myelomonocytic leukaemia) using an anti-GM-CSF neutralizing antibody https://ashpublications.org/ashclinicalnews/news/8658/Patients-With-CMML-Show-Durable-Response-to  . Recently, members of his team led by Professor Hiwase described a new form of autoimmune disease linked to IDH1 mutations in cancer (Blood, 2024).

Other research contributions include (i)  mutation-specific drug targets for acute myeloid leukaemia (EZH2 for AML with WT1 mutation, Blood 2015; Bcl2 as a target for cancer with IDH1 mutation, Nature Med 2016; ROS activation for AML with NPM1 mutation, Leukemia 2014; ACC1 for AML with IDH1 mutation, Nature Com, 2017), (ii) prediction of 145,891 synthetic partners for 3,120 recurrent mutations for 12 cancer types (Leukemia 2019, first author and co-inventor Nature Com, 2017, (iii) pre-clinical development of a biological therapy (humanized monoclonal antibody directed against CD123 Cell Stem Cell, 2009, Leukemia 2014) (iv) pre-clinical development of a biological therapy for myelofibrosis (Science Adv 2018), (v) repurposing medicines for treatment of leukaemia (JCI 2020, Scientific Reports 2019, J of Hepatology 2020) and (iv) translational experience in the Stanford Alliance for Innovative Medicines program.

Dr Thomas has been awarded a number of prizes for his work including the CSL Centenary Fellowship ($1.25M), K99-R00 Pathway to Independence award by the National Cancer Institute, NHMRC PhD award, Albert Bakie Medal, Douglas Hardy Prize, Nimmo Prize and CJ Martin Biomedical Fellowship, The Hospital Research Foundation 2020, 2 Ideas grants NHMRC 2020, MRFF funding 2020 for a precision medicine trial "Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort ". Dr Thomas received competitive grant funding for the 2020, 2022 and 2023 Translational Research Program/ Synergistic Team Awards from United States Leukemia & Lymphoma Society co-funded by The Leukaemia Foundation and Snowdome.

The over-arching goal of Dan’s research is to find novel mutation-specific drug targets for somatic mutations, especially in poor prognosis and difficult to treat cancer types, using leukemia as a test bed. The lab has unique skills in developing humanized in vivo models for AML, isolation and testing of pre-leukemia stem cells and bioinformatic algorithms together with key academic and industry networks.

Links to more information about The Myeloid Metabolism Lab:-

https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-21-0218/710553/Dysregulated-lipid-synthesis-by-oncogenic-IDH1

https://www.abc.net.au/news/2022-03-25/researchers-discover-potential-treatment-for-rare-cancer/100938498

https://www.leukaemia.org.au/stories/an-antibody-for-myelofibrosis-thats-a-true-discovery/

https://www.leukaemia.org.au/stories/a-new-era-of-medicine/ 

https://www.snowdome.org.au/science/prof-ravi-majeti-and-dr-daniel-thomas-are-uncovering-new-methods-to-switch-off-and-destroy-cancer-cells/

https://www.adelaide.edu.au/newsroom/news/list/2020/06/29/162-million-for-rare-cancer-research

https://www.cslfellowships.com.au/fellows-archive/associate-professor-daniel-thomas-bio

https://ndlr.com.au/

Date Position Institution name
2022 - ongoing Haematology Consultant Royal Adelaide Hospital
2019 - ongoing Titleholder Stanford University School of Medicine
2019 - ongoing Myeloid Metabolism Lab Leader and Program Leader Blood Cancer, Precision Medicine Theme South Australian Health and Medical Research Institute
2019 - ongoing CSL Fellow and Associate Professor The University of Adelaide
2017 - 2019 Instructor/Junior Faculty Stanford University School of Medicine
2010 - 2012 Staff Specialist Royal Adelaide Hospital
2000 - 2000 Resident Royal Adelaide Hospital

Date Type Title Institution Name Country Amount
2018 Award Stanford Alliance of Innovative Medicines Award Stanford University United States -
2015 Award Honorary Award for Outstanding Presentation, Stanford Hematology-Oncology Retreat Stanford University School of Medicine United States -
2015 Award Outstanding External Grant Reviewer for 2014 National Health and Medical Research Council of Australia Australia -
2014 Award Best Publication for Previous Year Centre for Cancer Biology Australia -
2014 Award Leukemia Foundation New Investigator Award Leukemia Foundation Australia -
2014 Award Outstanding Young Investigator Award, New Directions in Leukemia Research Conference New Directions in Leukemia Research Australia -
2012 Distinction Dean’s Commendation for Doctoral Thesis Excellence for PhD The University of Adelaide Australia -
2012 Fellowship CJ Martin Overseas Biomedical Fellowship NHMRC Australia $375,828
2011 Fellowship HOTT Haematology/Oncology Targetted Therapy Fellowship Haematology Society of Australia & New Zealand/COSA/Roche/COGA Australia -
2010 Award Nimmo Prize, Best Full-Time Research Royal Adelaide Hospital Australia -
2010 Award Outstanding Research Presentation Prize, New Directions in Leukaemia Conference New Directions in Leukaemia Research (NDLR) Australia -
2010 Fellowship HSANZ Haematology Targeted Therapy Fellowship The Haematology Society of Australia and New Zealand Australia -
2008 Award National Adult Medicine Research Award Royal Australasian College of Physicians Australia -
2007 Award Albert Baikie Memorial Medal Haematology Society of Australia & New Zealand Australia -
2007 Award John Chalmers Prize for Best Medical Research Presentation Royal Australasian College of Physicians Australia -
2007 Scholarship The NHMRC Postgraduate Scholarship National Health & Medical Research Council Australia -
2004 Award Hugh Gilmore Prize for Best Presentation of Medical Research by a Physician in Training Royal Adelaide Hospital Australia -

Date Institution name Country Title
2012 University of Adelaide Australia PhD
2000 University of Adelaide Australia Bachelor of Medicine and Bachelor of Surgery
1998 University of Adelaide Australia Bachelor of Medical Science (Honours)

Date Title Institution Country
2012 - 2013 Postdoctoral Fellow Stanford University School of Medicine United States

Date Title Institution name Country
2007 Fellow (FRACP) Royal Australasian College of Physicians Australia
2007 Fellow (FRCPA) Royal College of Pathologists of Australasia Australia

Year Citation
2025 Kan, W. L., Weekley, C. M., Nero, T. L., Hercus, T. R., Yip, K. H., Tumes, D. J., . . . Parker, M. W. (2025). The β Common Cytokine Receptor Family Reveals New Functional Paradigms From Structural Complexities. Immunological Reviews, 329(1), e13430-1-e13430-25.
DOI Scopus1 WoS3 Europe PMC1
2025 Robinson, N., Polara, R., & Thomas, D. (2025). IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer. Signal Transduction and Targeted Therapy, 10(1, article no 52), 52-1-52-3.
DOI Scopus2 WoS1 Europe PMC2
2025 Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., . . . Hiwase, D. K. (2025). Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Advances, 9(13), 3370-3380.
DOI Scopus6 WoS4 Europe PMC5
2025 Hansman, D. S., Lim, K., Thomas, D., Casson, R. J., & Peet, D. J. (2025). Distinct metabolome and flux responses in the retinal pigment epithelium to cytokines associated with age-related macular degeneration: comparison of ARPE-19 cells and eyecups. Scientific Reports, 15(1), 13012-1-13012-17.
DOI
2025 Shah, M. V., Hung, K., Baranwal, A., Wechalekar, G., Al-Kali, A., Toop, C. R., . . . Hiwase, D. (2025). Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer Journal, 15(1), 88-1-88-11.
DOI Scopus2 WoS2 Europe PMC1
2025 Kok, C. H., Al-Kali, A., Thomas, D., He, R., Kutyna, M. M., Alkhateeb, H. B., . . . Hiwase, D. K. (2025). RAS Mutation Identifies a Poor Prognostic Molecular Subtype of Therapy-Related Myeloid Neoplasm. Blood Advances, 9(15), 3814-3818.
DOI
2024 Landberg, N., Köhnke, T., Feng, Y., Nakauchi, Y., Fan, A. C., Linde, M. H., . . . Majeti, R. (2024). IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation.. Blood Cancer Discov, 5(2), 114-131.
DOI Scopus17 WoS17 Europe PMC11
2024 Calabrese, C., Nolte, H., Pitman, M. R., Ganesan, R., Lampe, P., Laboy, R., . . . Robinson, N. (2024). Mitochondrial translocation of TFEB regulates complex I and inflammation.. EMBO Reports, 25(2), 704-724.
DOI Scopus9 WoS9 Europe PMC10
2024 Hong, L. E., Wechalekar, M. D., Kutyna, M. M., Small, A., Lim, K., Thompson-Peach, C. A., . . . Hiwase, D. K. (2024). IDH-Mutant Myeloid Neoplasms are Associated with Seronegative Rheumatoid Arthritis and Innate Immune Activation. Blood, 143(18), 1873-1877.
DOI Scopus12 WoS11 Europe PMC11
2024 Hansman, D. S., Ma, Y., Thomas, D., Smith, J. R., Casson, R. J., & Peet, D. (2024). Metabolic Reprogramming of the Retinal Pigment Epithelium by Cytokines Associated with Age-related Macular Degeneration. Bioscience Reports, 44(4), BSR20231904.-1-BSR20231904.-20.
DOI Scopus9 WoS9 Europe PMC10
2024 Wechalekar, M. D., Zhao, L. -P., Kutyna, M. M., Hong, L. E., Li, J., Hung, K., . . . Hiwase, D. K. (2024). Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features. Blood Cancer Journal, 14(1), 116-1-116-5.
DOI Scopus2 WoS1 Europe PMC1
2024 Lim, K., Kan, W. L., Nair, P. C., Kutyna, M., Lopez, A. F., Hercus, T., . . . Thomas, D. (2024). CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting. PLoS One, 19(9), e0310641-1-e0310641-19.
DOI Scopus1 Europe PMC1
2023 Thomas, D., Wu, M., Nakauchi, Y., Zheng, M., Thompson-Peach, C. A., Lim, K., . . . Majeti, R. (2023). Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discovery, 13(2), 496-515.
DOI Scopus47 WoS43 Europe PMC46
2023 Hiwase, D. K., Hahn, C. N., Tran, E. N. H., Chhetri, R., Baranwal, A., Al-Kali, A., . . . Shah, M. V. (2023). TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood, 141(9), 1087-1091.
DOI Scopus30 WoS27 Europe PMC27
2023 Foßelteder, J., Pabst, G., Sconocchia, T., Schlacher, A., Auinger, L., Kashofer, K., . . . Reinisch, A. (2023). Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities. Leukemia, 37(4), 843-853.
DOI Scopus11 Europe PMC12
2023 Shah, M. V., Tran, E. N. H., Shah, S., Chhetri, R., Baranwal, A., Ladon, D., . . . Hiwase, D. K. (2023). TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer Journal, 13(1), 51-1-51-9.
DOI Scopus33 WoS33 Europe PMC30
2023 Thompson-Peach, C. A. L., Foßelteder, J., Reinisch, A., & Thomas, D. (2023). Thrombopoietin-independent Megakaryocyte Differentiation of Hematopoietic Progenitor Cells from Patients with Myeloproliferative Neoplasms. Bio-protocol, 13(2).
DOI
2023 Kan, W. L., Dhagat, U., Hercus, T. R., Kaufmann, K. B., Nero, T. L., Zeng, A. G. X., . . . Lopez, A. (2023). Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia. Cancer Discovery, 13(8), 1922-1947.
DOI Scopus9 WoS8 Europe PMC9
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. Blood Cancer Discovery, 4(5), 352-364.
DOI Scopus16 WoS13 Europe PMC13
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 1 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
DOI
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 2 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
DOI
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary Methods from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
DOI
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary Figure S1 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
DOI
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary Movie from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
DOI
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 2 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
DOI
2023 Nair, P. C., Piehler, J., Tvorogov, D., Ross, D. M., Lopez, A. F., Gotlib, J., & Thomas, D. (2023). Supplementary File 1 from Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
DOI
2023 Sharplin, K., Proudman, W., Chhetri, R., Tran, E. N. H., Choong, J., Kutyna, M., . . . Hiwase, D. (2023). A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data. Cancers, 15(16), 1-14.
DOI Scopus4 WoS4 Europe PMC3
2022 Tvorogov, D., Thompson-Peach, C. A. L., Foßelteder, J., Dottore, M., Stomski, F., Onnesha, S. A., . . . Lopez, A. F. (2022). Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody. EMBO Reports, 23(4), e52904-1-e52904-12.
DOI Scopus22 WoS22 Europe PMC21
2022 Lewis, A. C., Pope, V. S., Tea, M. N., Li, M., Nwosu, G. O., Nguyen, T. M., . . . Pitson, S. M. (2022). Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.. Blood, 139(26), 3737-3751.
DOI Scopus37 WoS34 Europe PMC37
2022 Bassal, M. A., Samaraweera, S. E., Lim, K., Bernard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications, 13(1), 1-12.
DOI Scopus18 WoS19 Europe PMC16
2022 Bassal, M. A., Samaraweera, S. E., Lim, K., Benard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.. Nat Commun, 13(1), 4131.
DOI Scopus2 WoS2 Europe PMC1
2022 Downes, C. E., McClure, B. J., McDougal, D. P., Heatley, S. L., Bruning, J. B., Thomas, D., . . . White, D. L. (2022). JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies. Frontiers in Cell and Developmental Biology, 10(942053), 1-34.
DOI Scopus27 WoS25 Europe PMC22
2022 Kutyna, M. M., Kok, C. H., Lim, Y., Tran, E. N. H., Campbell, D., Paton, S., . . . Hiwase, D. K. (2022). A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure. Leukemia, 36(11), 2678-2689.
DOI Scopus17 WoS17 Europe PMC17
2022 Nakauchi, Y., Azizi, A., Thomas, D., Corces, M. R., Reinisch, A., Sharma, R., . . . Majeti, R. (2022). The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia. Blood Cancer Discovery, 3(4), 346-367.
DOI Scopus34 WoS34 Europe PMC31
2021 Sharplin, K., Wee, L. Y. A., Singhal, D., Edwards, S., Danner, S., Lewis, I., . . . Hiwase, D. K. (2021). Outcomes and health care utilization of older patients with acute myeloid leukemia.. Journal of geriatric oncology, 12(2), 243-249.
DOI Scopus6 WoS6 Europe PMC9
2021 Ross, D. M., Babon, J. J., Tvorogov, D., & Thomas, D. (2021). Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications. Haematologica, 106(5), 1244-1253.
DOI Scopus23 WoS22 Europe PMC18
2021 Singhal, D., Hahn, C. N., Feurstein, S., Wee, L. Y. A., Moma, L., Kutyna, M. M., . . . Hiwase, D. K. (2021). Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 35(11), 3245-3256.
DOI Scopus48 WoS46 Europe PMC44
2021 Lim, K., Thompson-Peach, C., & Thomas, D. (2021). Neonatal heel prick mass spectrometry identifies metabolic predictors of AML latency. Leukemia Research, 109, 1-3.
DOI Scopus2 WoS1 Europe PMC1
2021 Thomas, D. (2021). Machine learning finds new AML subtypes. Blood, 138(19), 1790-1792.
DOI Scopus2 Europe PMC2
2021 Benard, B. A., Leak, L. B., Azizi, A., Thomas, D., Gentles, A. J., & Majeti, R. (2021). Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia. Nature Communications, 12(1), 1-13.
DOI Scopus47 Europe PMC52
2020 Guan, Y., Chen, X., Wu, M., Zhu, W., Arslan, A., Takeda, S., . . . Peltz, G. (2020). The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy. Journal of Hepatology, 72(4), 16 pages.
DOI Scopus51 Europe PMC44
2020 Dutta, R., Zhang, T. Y., Köhnke, T., Thomas, D., Linde, M., Gars, E., . . . Majeti, R. (2020). Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2. Journal of Clinical Investigation, 130(4), 1843-1849.
DOI Scopus25 Europe PMC20
2019 Benard, B., Gentles, A. J., Köhnke, T., Majeti, R., & Thomas, D. (2019). Data mining for mutation-specific targets in acute myeloid leukemia. Leukemia, 33(4), 826-843.
DOI Scopus19 Europe PMC16
2019 Benard, B., & Thomas, D. (2019). Predicting response to new drugs in AML from simulation modelling: Value of the BEAT AML project as a validation resource. Leukemia Research, 80, 43-44.
DOI Scopus1 Europe PMC1
2019 Li, Y., Thomas, D., Deutzmann, A., Majeti, R., Felsher, D. W., & Dill, D. L. (2019). Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Scientific Reports, 9(1), 16775.
DOI Scopus18 Europe PMC15
2018 Gars, E., Kaur, S., & Thomas, D. (2018). Endothelin receptor emerges as a potential target of Hoxa9-mediated leukemogenesis. Leukemia Research, 75, 69-70.
DOI
2018 Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., . . . Lopez, A. F. (2018). Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances, 4(11), 1-12.
DOI Scopus46 WoS48 Europe PMC49
2017 Powell, J., Lewis, A., Zhu, W., Toubia, J., Pitman, M., Wallington-Beddoe, C., . . . Pitson, S. (2017). Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.. Blood, 129(6), 771-782.
DOI Scopus86 WoS80 Europe PMC74
2017 Sinha, S., Thomas, D., Chan, S., Gao, Y., Brunen, D., Torabi, D., . . . Dill, D. L. (2017). Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications, 8(1), 1-13.
DOI Scopus83 Europe PMC66
2017 Thomas, D., & Majeti, R. (2017). Optimizing next-generation AML therapy: Activity of mutant IDH2 inhibitor AG-221 in preclinical models. Cancer Discovery, 7(5), 459-461.
DOI Scopus15 Europe PMC11
2017 Thomas, D., & Majeti, R. (2017). Biology and relevance of human acute myeloid leukemia stem cells. Blood, 129(12), 1577-1585.
DOI Scopus391 Europe PMC350
2016 Thomas, D., & Majeti, R. (2016). Burning Fat Fuels Leukemic Stem Cell Heterogeneity. Cell Stem Cell, 19(1), 1-2.
DOI Scopus7 Europe PMC11
2016 Huang, M., Garcia, J. S., Thomas, D., Zhu, L., Truong Nguyen, L. X., Chan, S. M., . . . Mitchell, B. S. (2016). Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget, 7(46), 74917-74930.
DOI Scopus9 Europe PMC9
2016 Reinisch, A., Thomas, D., Corces, M. R., Zhang, X., Gratzinger, D., Hong, W. J., . . . Majeti, R. (2016). A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nature Medicine, 22(7), 812-821.
DOI Scopus183 Europe PMC164
2016 Smith, A. M., Dun, M. D., Lee, E. M., Harrison, C., Kahl, R., Flanagan, H., . . . Verrills, N. M. (2016). Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 7(30), 47465-47478.
DOI Scopus42 WoS41 Europe PMC36
2015 Mazumdar, C., Shen, Y., Xavy, S., Zhao, F., Reinisch, A., Li, R., . . . Majeti, R. (2015). Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell, 17(6), 675-688.
DOI Scopus175 Europe PMC170
2015 Raval, A., Behbehani, G. K., Nguyen, L. X. T., Thomas, D., Kusler, B., Garbuzov, A., . . . Mitchell, B. S. (2015). Reversibility of defective hematopoiesis caused by telomere shortening in telomerase knockout mice. PLoS ONE, 10(7), 1-20.
DOI Scopus25 Europe PMC25
2015 Reinisch, A., Etchart, N., Thomas, D., Hofmann, N. A., Fruehwirth, M., Sinha, S., . . . Strunk, D. (2015). Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood, 125(2), 249-260.
DOI Scopus200 Europe PMC182
2015 Sinha, S., Thomas, D., Yu, L., Gentles, A. J., Jung, N., Corces-Zimmerman, M. R., . . . Majeti, R. (2015). Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood, 125(2), 316-326.
DOI Scopus43 Europe PMC37
2015 Reinisch, A., Chan, S. M., Thomas, D., & Majeti, R. (2015). Biology and clinical relevance of acute myeloid leukemia stem cells. Seminars in Hematology, 52(3), 150-164.
DOI Scopus55 Europe PMC49
2015 Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W. J., . . . Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine, 21(2), 178-184.
DOI Scopus502 Europe PMC448
2014 Busfield, S., Biondo, M., Wong, M., Ramshaw, H., Lee, E., Ghosh, S., . . . Nash, A. (2014). Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia, 28(11), 2213-2221.
DOI Scopus125 WoS114 Europe PMC99
2013 Lonic, A., Powell, J., Kong, Y., Thomas, D., Holien, J., Truong, N., . . . Guthridge, M. (2013). Phosphorylation of serine 779 in fibroblast growth factor receptor 1 and 2 by protein Kinase C(epsilon) regulates Ras/mitogen-activated protein kinase signaling and neuronal differentiation. Journal of Biological Chemistry, 288(21), 14874-14885.
DOI Scopus16 WoS15 Europe PMC15
2013 Thomas, D., Powell, J., Vergez, F., Segal, D., Nguyen, N., Baker, A., . . . Guthridge, M. (2013). Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 122(5), 738-748.
DOI Scopus57 WoS56 Europe PMC50
2013 Lim, Y., Wright, J., Attema, J., Gregory, P., Bert, A., Smith, E., . . . Goodall, G. (2013). Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. Journal of Cell Science, 126(10), 2256-2266.
DOI Scopus173 WoS157 Europe PMC153
2013 Thomas, D., Powell, J., Green, B., Barry, E., Ma, Y., Woodcock, J., . . . Guthridge, M. (2013). Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biology, 11(3), 1-14.
DOI Scopus20 WoS17 Europe PMC21
2013 Huang, M., Thomas, D., Li, M. X., Feng, W., Chan, S. M., Majeti, R., & Mitchell, B. S. (2013). Role of cysteine 288 in nucleophosmin cytoplasmic mutations: Sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia, 27(10), 1970-1980.
DOI Scopus30 Europe PMC32
2012 Hercus, T., Broughton, S., Ekert, P., Ramshaw, H., Perugini, M., Grimbaldeston, M., . . . Lopez, A. (2012). The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors, 30(2), 63-75.
DOI Scopus63 WoS59 Europe PMC54
2010 Lopez, A., Hercus, T., Ekert, P., Littler, D., Guthridge, M., Thomas, D., . . . Parker, M. (2010). Molecular basis of cytokine receptor activation. IUBMB Life, 62(7), 509-518.
DOI Scopus64 WoS58 Europe PMC46
2010 Roberts, K. G., Smith, A. M., McDougall, F., Carpenter, H., Horan, M., Neviani, P., . . . Verrills, N. M. (2010). Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Research, 70(13), 5438-5447.
DOI Scopus125 WoS122 Europe PMC101
2009 Jin, L., Lee, E., Ramshaw, H., Busfield, S., Peoppl, A., Wilkinson, L., . . . Lock, R. (2009). Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 5(1), 31-42.
DOI Scopus466 WoS419 Europe PMC379
2009 Powell, J., Thomas, D., Barry, E., Kok, C., McClure, B., Tsykin, A., . . . Guthridge, M. (2009). Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood, 114(23), 4859-4870.
DOI Scopus53 WoS51 Europe PMC49
2009 Hercus, T., Thomas, D., Guthridge, M., Ekert, P., King-Scott, J., Parker, M., & Lopez, A. (2009). The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood, 114(7), 1289-1298.
DOI Scopus263 WoS252 Europe PMC212
2008 Lee, S., Ho, S., Thomas, D., Giri, P., Lee, H., Sia, H., . . . Sullivan, T. (2008). A partial nucleated differential cell count of the bone marrow aspirate that is independent of peripheral blood dilution. International Journal of Laboratory Hematology (Print Edition), 30(6), 473-479.
DOI Scopus3 WoS2 Europe PMC3
2006 Mitchell, E., Thomas, D., & Burnet, R. (2006). Testosterone improves motor function in Parkinson's disease. Journal of Clinical Neuroscience, 13(1), 133-136.
DOI Scopus52 Europe PMC39
2006 Guthridge, M., Powell, J., Barry, E., Stomski, F., Mc Clure, B., Ramshaw, H., . . . Lopez, A. (2006). Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO Journal, 25(3), 479-489.
DOI Scopus72 WoS71 Europe PMC69
2004 Thomas, D., Vadas, M., & Lopez, A. (2004). Regulation of haematopoiesis by growth factors - emerging insights and therapies. Expert Opinion on Biological Therapy, 4(6), 869-879.
DOI Scopus17 WoS16 Europe PMC17
1999 Stomski, F., Dottore, M., Winnall, W., Guthridge, M., Woodcock, J., Bagley, C., . . . Lopez, A. (1999). Identification of a 14-3-3 binding sequence in the common B chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 receptors that is serine-phosphorylated by GM-CSF. Blood, 94(6), 1933-1942.
DOI Scopus46 WoS39 Europe PMC29
1998 Guthridge, M. A., Stomski, F. C., Thomas, D., Woodcock, J. M., Bagley, C. J., Berndt, M. C., & Lopez, A. F. (1998). Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells, 16(5), 301-313.
DOI Scopus158 WoS150 Europe PMC126

Year Citation
2005 Thomas, D., Guthridge, M., Woodcock, J., & Lopez, A. (2005). Protein Signaling in Development and Growth Factor Responses (Vol. 67). G. P. Schatten (Ed.), ELSEVIER ACADEMIC PRESS INC.
DOI Scopus38 WoS36 Europe PMC31

Year Citation
2017 Sinha, S., Ravindra, M., Dill, D. L., & Thomas, D. (2017). WO/2017/083716, Determination of Synthetic Lethal Partners of Cancer-Specific Alterations and Methods of Use Thereof. United States.

 

Date Project/No. Investigators Funding Body Amount
2023-2025 Bioengineering a Superior Humanized Haematopoietic Niche Derived from Mesenchymal Stem Cells for Pre-Clinical Avatar Cancer Trials. MRF2024427 THOMAS D, Reinisch A, Thompson-Peach C, Powell J, Branford S, Arthur A, Pitson S, Hughes T, Ross D, Edney L. MRFF Stem Cell Therapies $854,594
2023 Anti-mutant CALR Antibody Preparation for Clinical Manufacture for Patients with Myelofibrosis. THOMAS D Therapeutic Innovation Australia Pipeline Accelerator $100,000
2022-2025 Identifying synthetic lethal and microenvironmental targets to improve outcome of therapy-related myeloid neoplasms. 2013617. Hiwase D, Hahn C, THOMAS D, Gronthos S, Godley L. Cancer Australia Priority-driven Collaborative Cancer Research Scheme. $563,770
2022-2025 Identification and Molecular Analysis of Pre-Myelofibrotic Stem Cells. FND000208.

THOMAS D, Majeti

R, Lopez A.

 Leukemia & Lymphoma Society US $600,000
2021-2026 Shining Light into the “unknown” on Indigenous and non-Indigenous Australians with Cancer of unknown Primary. MRF2007652 Karapetis C, Brown A, Kichendasse G, Pratt G, Scott H, Vajdic C, Waddell N, Corsini N, THOMAS D, Brown A. MRFF Improving Diagnosis in Cancers with Low Survival Rates. $2,401,509
2021-2024 ABOLISH Neuroblastoma: Defining the Aetiology and underlying BiOLogy of neuroblastoma to Innovate and SHape new options for prevention, diagnosis and treatment. MRF2007404. Khew-Goodall Y, Goodall G, Kirby M, Schwarz Q, Polo J, Wolvetang E, Pillman K, Jessop S, THOMAS D. MRFF Childhood Cancer Research $1,420,132
2021-2024 Engineered human stem cells for mutation-specific eradication of myelofibrosis. MRF2008972 THOMAS D, Reinisch A, Ross D, Babon J, Tvorogov D, Nair P, Morris R MRFF Stem Cell Therapies $853,275.
2020-2024 Targeting Macromolecule Biosynthesis in Cancer by in vivo Flux Measurement of Primary Cells for Rational Drug Development. IF1320. THOMAS D Beat Cancer Project Infrastructure Grant $153,120
2020-2023 Personalized Metabolic Targeting of Epigenetic AML Mutations Through the Alpha-Ketoglutarate Pathway. ID 6619-21. Majeti R, THOMAS D. The Leukemia and Lymphoma Society Translational Research Program US$649,998.
2020-2023 Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort. APP1201012. Hughes T, Hiwase D, Ross D, THOMAS D, Yeung D, Lane S, Yong A, Lopez A, Hercus T, Reynolds J. MRFF Rare Cancers Rare Diseases Unmet Need $1,619,122
2020-2022 Mutation-Centric Therapy for JAK2 vs CALR Mutated Myelofibrosis. APP1182564. Lopez A, Tvorogov D, THOMAS D NHMRC Ideas $661,237
2020-2022 Employing humanised xenotransplantation models of acute myeloid leukaemia to predict patient outcome and direct therapy. APP1184485. Pitson S, Powell J, THOMAS D. NHMRC Ideas $795,650
2020-2021 Pre-clinical Efficacy of ACC1 as a novel target for IDH1 Mutated Cancer. C-PJ-173-Exper-2019. THOMAS D. The Hospital Research Foundation Project Gran $69,000
2018-2019 Potent and Selective ACC1 inhibitor for Cancer with IDH1 Mutations THOMAS D, Majeti R. Stanford University US $75,000
2017-2022 Discovery of Synthetic Lethal Targets for Recurrent Epigenetic Mutations in Acute Myeloid Leukemia. APP ID 88686. THOMAS D. National Cancer Institute US $1,040,000
2014-2015 Data-Mining for Synthetic Lethal Targets in Acute Myeloid Leukemia. Majeti R, Dill D. L. National Institutes of Health US $500,000
2014-2015 SA PATH Equipment Grant. GNT9000253. Lopez A, Hughes T, Revesz T, THOMAS D. NHMRC $9,634
2012-2017 Targetting Quiescence Signalling Pathways in AML Stem Cells. APP1037514. THOMAS, D. NHMRC – Early Career Fellowship $274,434

Dr Thomas enjoys teaching and supervising 3rd year science students, Masters and PhD students in formal and informal sessions including regular Cancer Metabolism and Epigenetics journal club meetings at Level 4 SAHMRI Boardroom 2.30pm on Mondays

Date Role Research Topic Program Degree Type Student Load Student Name
2023 Principal Supervisor Discovery of novel metabolic targets against lDH1-mutant intrahepatic cholangiocarcinoma Doctor of Philosophy Doctorate Full Time Mrs Tasnova Tasnim Nova
2023 Principal Supervisor Novel Target Discovery for TP53 Mutated clonal Haematopoiesis Doctor of Philosophy Doctorate Full Time Mr Hossein Anani
2023 Co-Supervisor Fecal microbiota transplantation as an adjunctive supportive care therapy for haematopoietic stem cell transplantation recipients. Doctor of Philosophy Doctorate Full Time Miss Anna Li
2023 Principal Supervisor How Cancer Associated Fibroblasts Modify Stromal Landscape to Advance Malignant Progression of Breast Cancer Doctor of Philosophy Doctorate Full Time Mr Michael Antoniou
2023 Principal Supervisor The biological function of tryptophan metabolism in triple-negative breast cancer and cancer stem cells population Doctor of Philosophy Doctorate Full Time Mr Jamshid Motalebzadeh
2023 Principal Supervisor Peroxisome Biology in IDH1 Mutated Cancer Cells and Its potential for Target Therapy Doctor of Philosophy Doctorate Full Time Ms Mahta Moraghebi
2023 Co-Supervisor Synthetic lethality-based identification of metabolic targets for prostate cancer treatment Doctor of Philosophy Doctorate Full Time Mr Mohammad Asaad Ibrahim Ismail
2023 Principal Supervisor Modelling mutations in juvenile myelomonocytic leukaemia and chronic myelomonocytic leukaemia Doctor of Philosophy Doctorate Part Time Ms Kelly Lim
2023 Principal Supervisor How Cancer Associated Fibroblasts Modify Stromal Landscape to Advance Malignant Progression of Breast Cancer Doctor of Philosophy Doctorate Full Time Mr Michael Antoniou
2023 Principal Supervisor The biological function of tryptophan metabolism in triple-negative breast cancer and cancer stem cells population Doctor of Philosophy Doctorate Full Time Mr Jamshid Motalebzadeh
2023 Principal Supervisor Novel Target Discovery for TP53 Mutated clonal Haematopoiesis Doctor of Philosophy Doctorate Full Time Mr Hossein Anani
2023 Principal Supervisor Modelling mutations in juvenile myelomonocytic leukaemia and chronic myelomonocytic leukaemia Doctor of Philosophy Doctorate Part Time Ms Kelly Lim
2023 Co-Supervisor Synthetic lethality-based identification of metabolic targets for prostate cancer treatment Doctor of Philosophy Doctorate Full Time Mr Mohammad Asaad Ibrahim Ismail
2023 Principal Supervisor Discovery of novel metabolic targets against lDH1-mutant intrahepatic cholangiocarcinoma Doctor of Philosophy Doctorate Full Time Mrs Tasnova Tasnim Nova
2023 Co-Supervisor Fecal microbiota transplantation as an adjunctive supportive care therapy for haematopoietic stem cell transplantation recipients. Doctor of Philosophy Doctorate Full Time Miss Anna Li
2023 Principal Supervisor Peroxisome Biology in IDH1 Mutated Cancer Cells and Its potential for Target Therapy Doctor of Philosophy Doctorate Full Time Ms Mahta Moraghebi
2022 Principal Supervisor A humanized monocyte model of TET2 mutated clonal hematopoiesis for noel target discovery Doctor of Philosophy Doctorate Full Time Miss Maha Kamel
2022 Principal Supervisor A humanized monocyte model of TET2 mutated clonal hematopoiesis for noel target discovery Doctor of Philosophy Doctorate Full Time Miss Maha Kamel

Date Role Research Topic Location Program Supervision Type Student Load Student Name
2021 - 2022 Principal Supervisor Discovering Novel Approaches in the Treatment of CALR mutant Myelofibosis University of Adelaide - Master - Suraiya Onnesha
2021 - 2021 Principal Supervisor A human cell model of juvenile myelomonocytic leukemia with a PTPN11 mutation University of Adelaide - Honours - Kzandrea Magday
2018 - 2018 Principal Supervisor Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethality vulnerability Stanford University - Other - Satinder Kaur

Date Topic Location Name
2019 - 2023 Clonal architecture predicts clinical outcome and drug sensitivity Stanford University Brooks Bernard

Date Role Committee Institution Country
2022 - ongoing Member Acute Leukaemia and Myelodysplasia Working Committee Australasian Leukaemia and Lymphoma Group Australia
2022 - ongoing Member Braggs Comprehensive Cancer Centre Adelaide Health Innovation Partnership Australia

Date Title Type Institution Country
2019 - ongoing Associate Reviewer Peer Review Blood United States
2019 - ongoing Editor Peer Review PLOS ONE United States

Connect With Me

External Profiles

Other Links